VT3989 (TEAD inhibitor)
Vivace Therapeutics
VT3989 is a TEAD inhibitor by Vivace Therapeutics that is currently in phase 1 for NF2-mutant tumors (NCT04665206).
I’ve been keeping an eye on this compound for some time. Earlier this month, Vivace Therapeutics closed a $35M Series D to push VT3989 towards a registrational phase 3 trial in mesothelioma. Figured it was time to crack this one open again :^)
Have a compound that you want me look into? Suggest a compound here.